Ticker	Volume	Price	Price Delta
DJIA	15,307.20	-80.41	-0.52%
S&P 500	1,655.35	-13.81	-0.83%
Nasdaq	3,463.30	-38.82	-1.11%

Ticker

Volume

Price

Price Delta

DJIA

15,307.20

-80.41

-0.52%

S&P 500

1,655.35

-13.81

-0.83%

Nasdaq

3,463.30

-38.82

-1.11%

Ticker	Volume	Price	Price Delta
STOXX 50	2,835.01	+13.36	0.47%
FTSE 100	6,840.27	+36.40	0.53%
DAX	8,530.89	+58.69	0.69%

Ticker

Volume

Price

Price Delta

STOXX 50

2,835.01

+13.36

0.47%

FTSE 100

6,840.27

+36.40

0.53%

DAX

8,530.89

+58.69

0.69%

Ticker	Volume	Price	Price Delta
Nikkei	15,627.30	+246.24	1.60%
Hang Seng	23,261.10	-105.29	-0.45%
S&P/ASX 200	5,165.37	-14.69	-0.28%

Ticker

Volume

Price

Price Delta

Nikkei

15,627.30

+246.24

1.60%

Hang Seng

23,261.10

-105.29

-0.45%

S&P/ASX 200

5,165.37

-14.69

-0.28%

House’s Camp Says He’ll Get Treatment for Non-Hodgkins Lymphoma

By Steve Geimann - 2012-07-28T18:24:14Z

U.S. House Ways and Means Committee Chairman Dave Camp, a Michigan Republican, said he will begin chemotherapy treatment for non-Hodgkins lymphoma that he said was discovered during a routine annual physical examination.

Camp said in a statement today that he will continue to represent his constituents and work as chairman of the committee that develops U.S. tax policy.

“My treatment will take place every three weeks over the next few months,” Camp said. “My doctors and I expect a full recovery and cure.”

To contact the reporter on this story: Steve Geimann in Washington at sgeimann@bloomberg.net

To contact the editor responsible for this story: Steve Geimann at sgeimann@bloomberg.net

More News:

U.S.

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.